{"id":60882,"date":"2024-02-28T07:13:05","date_gmt":"2024-02-28T07:13:05","guid":{"rendered":"https:\/\/medsname.com\/dytor\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"dytor","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/dytor\/","title":{"rendered":"Dytor"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Dytor?<\/h3>\n<p style=\"margin:0;\"><strong>Dytor<\/strong> er en <strong>5 \/ 10 \/ 20 mg torasemide tablet<\/strong> from Cipla &mdash; a <strong>loop diuretic (pyridine-sulfonylurea structure)<\/strong> der virker p\u00e5 <strong>NKCC2 (Na-K-2Cl cotransporter) in the thick ascending limb<\/strong>. Torasemide (torsemide in US nomenclature) was introduced by Boehringer Mannheim in 1993 &mdash; the third major loop diuretic after furosemide and bumetanide. Marketed on its predictable bioavailability and longer duration vs furosemide. Half-life 3-4 hours (longer than furosemide); onset 30-60 minutes; peak effect 1-2 hours; duration 6-8 hours. Primary indication: <strong>chronic heart-failure oedema, hypertension (including refractory), hepatic ascites, oedema of chronic kidney disease<\/strong>. Typisk dosering: <strong>Hypertension:<\/strong> 5-10 mg once daily in the morning. Torasemide is the <strong>only loop diuretic with reasonable antihypertensive evidence<\/strong> &mdash; its longer effect duration and additional anti-aldosterone\/anti-fibrotic activity make it better suited for once-daily BP control than furosemide. Key contraindications: see full list below. Monitor electrolytes, creatinine, and glucose. <strong>Kombiner ikke med lithium<\/strong> (thiazid-\/loop-diuretika kan fremskynde lithiumtoksicitet). <strong>Brug under graviditet er tilf\u00e6ldesspecifik<\/strong> (se graviditetsnote). For de fleste hypertensionspatienter virker diuretika bedst som <strong>andet eller tredje middel<\/strong> \u2014 typisk kombineret med en ARB, ACE-h\u00e6mmer eller calciumkanalblokerer snarere end brugt alene.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede <a href=\"https:\/\/medsbase.com\/da\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er d\u00e6kket af vores <a href=\"https:\/\/medsbase.com\/da\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n<h2 class=\"wp-block-heading\">What Is Dytor?<\/h2>\n<p>Dytor is an oral 5 \/ 10 \/ 20 mg torasemide tablet from Cipla, supplied in 30-180 tablets. Torasemide (torsemide in US nomenclature) was introduced by Boehringer Mannheim in 1993 &mdash; the third major loop diuretic after furosemide and bumetanide. Marketed on its predictable bioavailability and longer duration vs furosemide.<\/p>\n<h2 class=\"wp-block-heading\">How Torasemide Works<\/h2>\n<p>Torasemide inhibits the <strong>NKCC2 (Na-K-2Cl cotransporter) in the thick ascending limb<\/strong>. De nedstr\u00f8mmende effekter:<\/p>\n<ul>\n<li><strong>Dramatisk reduktion i natriumreabsorption<\/strong> \u2014 l\u00f8kkediuretika blokerer det st\u00f8rste natriumreabsorberende segment af nefronet; op til 25% af filtreret natrium kan udskilles<\/li>\n<li><strong>Stor diurese<\/strong> inden for 1-2 timer efter oral dosering (5 minutter intraven\u00f8st) \u2014 nyttig ved akut dekompenseret hjertesvigt og lunge\u00f8dem<\/li>\n<li><strong>Tab af magnesium og calcium<\/strong> udover natrium og kalium \u2014 i mods\u00e6tning til thiazider, der tilbageholder calcium<\/li>\n<li><strong>Direkte venodilatation<\/strong> inden for f\u00e5 minutter efter intraven\u00f8s dosering \u2014 bidrager til symptombedring ved akut lunge\u00f8dem f\u00f8r diuresen indtr\u00e6ffer<\/li>\n<li><strong>Aktiverer prostaglandinsyntese<\/strong> i nyrerne \u2014 grundlaget for NSAID-interaktionen (NSAID'er d\u00e6mper l\u00f8kkediuretikums effekt)<\/li>\n<li><strong>Mild mineralocorticoid receptor antagonism<\/strong> &mdash; reduces hypokalaemia and provides partial anti-fibrotic activity on myocardium<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Godkendte og evidensbaserede anvendelser<\/h2>\n<ul>\n<li><strong>Chronic heart-failure oedema, hypertension (including refractory), hepatic ascites, oedema of chronic kidney disease<\/strong> \u2014 prim\u00e6r indikation<\/li>\n<li><strong>Chronic heart failure with oedema<\/strong><\/li>\n<li><strong>Leverskade-relateret ascites<\/strong> (kombineret med spironolacton)<\/li>\n<li><strong>Hypertension, including refractory hypertension<\/strong> (only loop diuretic with reasonable HTN evidence)<\/li>\n<li><strong>CKD-related oedema<\/strong> &mdash; effective at eGFR &lt;30 where thiazides fail<\/li>\n<li><strong>Furosemide non-response<\/strong> &mdash; switching to torasemide often restores response due to better bioavailability<\/li>\n<\/ul>\n<p><strong>Afg\u00f8rende kliniske fors\u00f8gsresultater:<\/strong> <strong>TORIC trial (2002)<\/strong> &mdash; observational study of 1,377 HF patients; torasemide vs furosemide, torasemide arm showed 52% lower mortality. Widely cited but criticised for non-randomised design. <strong>TRANSFORM-HF (2023)<\/strong> &mdash; large randomised trial of 2,859 HF patients, torasemide vs furosemide; <strong>no significant difference<\/strong> in all-cause mortality at 12 months. Current verdict: torasemide is at least as good as furosemide; the choice turns on bioavailability, convenience, and tolerability rather than mortality.<\/p>\n<h2 class=\"wp-block-heading\">Dytor Dosage<\/h2>\n<p><strong>Chronic dose:<\/strong> <strong>Hypertension:<\/strong> 5-10 mg once daily in the morning. Torasemide is the <strong>only loop diuretic with reasonable antihypertensive evidence<\/strong> &mdash; its longer effect duration and additional anti-aldosterone\/anti-fibrotic activity make it better suited for once-daily BP control than furosemide.<\/p>\n<p><strong>Andre indikationer:<\/strong> <strong>Hjertesvigt:<\/strong> 10-20 mg PO daily initially; titrate to 10-100 mg\/day. Once-daily dosing is typically adequate. <strong>Leverskrumpe med ascites:<\/strong> 5-40 mg\/day in combination with spironolactone 100-200 mg\/day. <strong>CKD oedema:<\/strong> higher doses required (20-100 mg\/day) as nephrons drop.<\/p>\n<p><strong>Administration:<\/strong> \u00e9n gang dagligt (eller to gange dagligt for h\u00f8j dosis loop-diuretika ved HF), om morgenen. Aftendosering for\u00e5rsager nokturi og b\u00f8r undg\u00e5s n\u00e5r muligt. Tag p\u00e5 samme tidspunkt hver dag. Mad p\u00e5virker ikke absorptionen markant for nogen af disse diuretika.<\/p>\n<p><strong>Overv\u00e5gningsplan:<\/strong><\/p>\n<ul>\n<li><strong>Baseline:<\/strong> harnstoff, elektrolytter (is\u00e6r kalium og natrium), kreatinin, eGFR, glukose, serumurat. Hjemme- eller klinikblodtryk og daglig v\u00e6gt for HF-patienter.<\/li>\n<li><strong>1-2 uger efter start eller dosis\u00e6ndring:<\/strong> gentag U&amp;E og kreatinin. Forvent milde elektrolyt\u00e6ndringer; unders\u00f8g v\u00e6sentlige \u00e6ndringer.<\/li>\n<li><strong>4-6 uger:<\/strong> Blodtryksgennemgang og fuldt metabolisk panel.<\/li>\n<li><strong>L\u00f8bende:<\/strong> \u00e5rlig U&amp;E, urat, glukose og lipidpanel n\u00e5r stabiliseret. Hyppigere ved CKD, HF eller ved kombinationsterapi.<\/li>\n<li><strong>Stop eller reducer dosis ved:<\/strong> natrium &lt;130 med symptomer, kalium 5,5, kreatininstigning &gt;30%, nyt gigt, alvorlige dehydreringssymptomer.<\/li>\n<\/ul>\n<p><strong>Oph\u00f8r:<\/strong> ingen abstinenssyndrom, men pludselig stop kan for\u00e5rsake rebound-volumenretention hos HF-patienter p\u00e5 kronisk h\u00f8j dosis loop-diuretika \u2014 trapp ned hvor muligt og overv\u00e5g v\u00e6gt.<\/p>\n<ul>\n<li><strong>Bioavailability 80-100%<\/strong> (furosemide 10-90%) &mdash; particularly useful in patients with congested heart failure, gut oedema, or inconsistent response to furosemide.<\/li>\n<li><strong>Mild aldosterone antagonism<\/strong> &mdash; partial anti-fibrotic activity in myocardium. Clinical significance modest; probably contributes to why TORIC showed benefit.<\/li>\n<li><strong>Less hypokalaemic<\/strong> than furosemide at equivalent natriuretic doses (related to the aldosterone-antagonist effect).<\/li>\n<li><strong>Equivalence dosing:<\/strong> torasemide 10 mg &asymp; furosemide 40 mg. Useful when switching patients between agents.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bivirkninger<\/h2>\n<p><strong>Almindelige (&gt;1%):<\/strong><\/p>\n<ul>\n<li><strong>Hypokali\u00e6mi<\/strong> (less than furosemide)<\/li>\n<li><strong>Hypomagnesi\u00e6mi<\/strong><\/li>\n<li><strong>Hyponatri\u00e6mi<\/strong><\/li>\n<li><strong>Pre-renal AKI<\/strong> in over-diuresis<\/li>\n<li><strong>Ototoksicitet<\/strong> (rare; less than furosemide per unit of natriuresis)<\/li>\n<li><strong>Hyperurik\u00e6mi<\/strong><\/li>\n<li><strong>Mild hyperglyk\u00e6mi<\/strong><\/li>\n<li><strong>Postural hypotension<\/strong><\/li>\n<li><strong>Svimmelhed, hovedpine<\/strong><\/li>\n<\/ul>\n<p><strong>Ikke almindelige, men klinisk vigtige:<\/strong><\/p>\n<ul>\n<li><strong>Alvorlig hyponatri\u00e6mi<\/strong> \u2014 is\u00e6r hos \u00e6ldre med lav-salt di\u00e6t, SIADH-tilb\u00f8jelige tilstande eller kombineret med SSRI. Kan vise sig som forvirring, fald eller krampeanfald.<\/li>\n<li><strong>Pankreatitis<\/strong> \u2014 sj\u00e6lden thiazid-\/loop-virkning; stop umiddelbart ved \u00f8vre mavesmerter med stigning i lipase<\/li>\n<li><strong>Trombocytopeni, leukopeni, agranulocytose<\/strong> \u2014 sj\u00e6ldne overf\u00f8lsomhedsreaktioner (mere almindelige med thiazider end loop-diuretika)<\/li>\n<li><strong>Akut myopi og vinkelblokglaukom<\/strong> \u2014 sj\u00e6lden sulfonamid-klassereaktion inden for timer til dage efter start; stop umiddelbart ved pludselig \u00f8jensmerte eller syns\u00e6ndring<\/li>\n<li><strong>Stevens-Johnson syndrom \/ toksisk epidermal nekrolyse<\/strong> \u2014 ekstremt sj\u00e6ldent, men rapporteret<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikationer<\/h2>\n<ul>\n<li>Anuri<\/li>\n<li>Overf\u00f8lsomhed overfor sulfonamider<\/li>\n<li>Severe hepatic failure with hepatic coma<\/li>\n<li>Severe hyponatraemia or hypokalaemia at baseline<\/li>\n<li>Alvorlig dehydrering og prerenal azot\u00e6mi<\/li>\n<\/ul>\n<p><strong>Graviditet:<\/strong> undg\u00e5s til rutinem\u00e6ssig hypertension; kun til klar indikation (lunge\u00f8dem, resistent HF) under specialisterapi. Sl\u00f8jfedemidler passerer placenta og kan reducere fosterets urinproduktion.<\/p>\n<p><strong>Amning:<\/strong> generelt acceptabelt i lave doser; h\u00f8je doser kan h\u00e6mme laktation (is\u00e6r thiazider). Alternative antihypertensiva (propranolol, nifedipin) foretr\u00e6kkes, n\u00e5r muligt.<\/p>\n<h2 class=\"wp-block-heading\">L\u00e6gemiddelinteraktioner<\/h2>\n<ul>\n<li><strong>Lithium \u2014 KRITISK INTERAKTION.<\/strong> Thiazid- og loop-diuretika reducerer lithiums renale clearance og kan udl\u00f8se lithiumforgiftning. Undg\u00e5 kombination, hvis muligt; hvis uundg\u00e5elig, monitorer lithiumniveauer ugentligt den f\u00f8rste m\u00e5ned og reducer lithiumdosis med 25-50%.<\/li>\n<li><strong>NSAID'er<\/strong> \u2014 reducerer diuretisk effekt (via prostaglandinh\u00e6mning) og \u00f8ger betydeligt risiko for akut nyreskade, n\u00e5r kombineret med ACE-h\u00e6mmer\/ARB (\u201ctriple whammy\u201d). Brug paracetamol som foretrukket ved kroniske smerter.<\/li>\n<li><strong>ACE-h\u00e6mmere og ARB<\/strong> \u2014 kombinationen er standard og gavnlig ved HTN; ACE-h\u00e6mmer\/ARB-tilf\u00f8jelse blokerer kompensatorisk RAAS-aktivering og potentierer den diuretiske effekt. Monitorer kalium og kreatinin.<\/li>\n<li><strong>Kaliumtilskud og kaliumbesparende diuretika<\/strong> \u2014 ofte n\u00f8dvendigt for at modvirke loop-\/thiazid-induceret hypokali\u00e6mi. Monitorer kalium; undg\u00e5 overkorrektion.<\/li>\n<li><strong>Digoxin<\/strong> \u2014 hypokalaemi forst\u00e6rker digoxin-toksicitet (loop- og thiaziddiuretika); spironolacton reducerer digoxin-klaring direkte. Overv\u00e5g digoxinniveauer og kalium ved p\u00e5begyndelse eller \u00e6ndring af diuretikum.<\/li>\n<li><strong>Orale kortikosteroider, amphotericin B, stimulerende aff\u00f8ringsmidler<\/strong> \u2014 additiv hypokalaemi (loop-\/thiazid) eller maskeret kaliumbehov (spironolacton).<\/li>\n<li><strong>Orale antidiabetika, insulin<\/strong> \u2014 thiazider og (i mindre grad) loop-diuretika forv\u00e6rrer glucosetolerance; kan kr\u00e6ve dosisjustering.<\/li>\n<li><strong>Cholestyramin \/ colestipol<\/strong> \u2014 reducerer absorptionen af thiazider og loop-diuretika med 40-85%. Adskil dosering med 4 timer.<\/li>\n<li><strong>Aminoglykosidantibiotika (gentamicin, amikacin)<\/strong> \u2014 additiv ototoksicitet. Undg\u00e5 samtidig brug ved h\u00f8je IV-doser.<\/li>\n<li><strong>Alkohol<\/strong> \u2014 additiv postural hypotension.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Where Dytor Fits in the Diuretic Class<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:14px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Klasse<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Repr\u00e6sentanter<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Typisk anvendelse<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Thiazid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/da\/aquazide\/\">HCTZ<\/a>, chlorthalidon<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">F\u00f8rstevalg ved HTN, nyresten, nefrogen DI<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Thiazid-lignende<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/da\/natrilix-sr\/\">Indapamid<\/a>, metolazon<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">HTN (\u00e6ldre, HYVET-evidence), sekventiel nefronblokade<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Loop (kort)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/da\/lasix\/\">Furosemid<\/a>, bumetanid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Akut lunge\u00f8dem, CHF, ascites, hyperkalc\u00e6mi<\/td>\n<\/tr>\n<tr style=\"background:#fff3cd;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Loop (lang)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/da\/dytor\/\">Torasemid<\/a><\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kronisk CHF, HTN (eneste loop med HTN-evidence), CKD-\u00f8dem<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aldosteronantagonist<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\"><a href=\"https:\/\/medsbase.com\/da\/aldactone\/\">Spironolakton<\/a>, eplerenone<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">HF-REF (RALES), resistent HTN (PATHWAY-2), Conn\u2019s, cirrhotisk ascites<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:10px;border:1px solid #ddd;\">Anden kaliumbesparende<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Amilorid, triamteren (normalt i kombinationer)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Forebyggelse af hypokali\u00e6mi ved tilf\u00f8jelse til loop\/thiazid<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Carbonic anhydrase<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Acetazolamid<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">H\u00f8jdesyge, glaukom, metabol alkalose<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Opbevaring<\/h2>\n<p>Store Dytor below 25&deg;C in the original blister pack. Keep out of reach of children.<\/p>\n<h2 id=\"faqs\">Ofte stillede sp\u00f8rgsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">When should I take Dytor &mdash; morning or evening?<\/h3>\n<p><strong>Morgen<\/strong> i n\u00e6sten alle tilf\u00e6lde. Den diuretiske effekt \u00f8ger urinproduktionen i 2-4 timer efter dosering. Aftendosering for\u00e5rsager nokturi og forstyrrer s\u00f8vnen. Patienter p\u00e5 to-daglige sl\u00f8jfedemidler doserer typisk ved morgenmad og tidlig eftermiddag (ikke sengetid).<\/p>\n<h3 class=\"wp-block-heading\">Is Dytor a first-line blood-pressure drug?<\/h3>\n<p><strong>Nej.<\/strong> Loop-diuretika er <strong>ikke f\u00f8rstevalgs antihypertensiva<\/strong> \u2014 de virker for kortvarigt og for\u00e5rsager blodtryksudsving. Loop-diuretika bruges kun ved hypertension i specifikke situationer: samtidig hjerteinsufficiens med \u00f8dem, fremskreden nyresvigt (eGFR &lt;30) hvor thiazider ikke virker, eller resistent hypertension som till\u00e6gsbehandling. Ved almindelig hypertension b\u00f8r man i stedet v\u00e6lge en thiazid, ARB, ACE-h\u00e6mmer eller calciumkanalblokker.<\/p>\n<h3 class=\"wp-block-heading\">Will Dytor affect my potassium?<\/h3>\n<p>Yes &mdash; Dytor <strong>s\u00e6nker<\/strong> kalium ved at \u00f8ge den distale tubulus' kaliumudskillelse. Overv\u00e5g ved baseline, efter 1-2 uger og periodisk. Risikoen for hypokali\u00e6mi er <strong>minimeret ved at kombinere<\/strong> Dytor with an ARB or ACE inhibitor &mdash; which is the standard combination in hypertension anyway. If potassium drops below 3.5 in isolated diuretic use, add potassium supplementation, a potassium-rich diet, or a small dose of a potassium-sparing agent (spironolactone, eplerenone, or an <a href=\"https:\/\/medsbase.com\/da\/amifru\/\">amiloridholdig kombination<\/a>).<\/p>\n<h3 class=\"wp-block-heading\">I have gout &mdash; can I take Dytor?<\/h3>\n<p>Med forsigtighed. Thiazider og (i mindre grad) loop-diuretika \u00f8ger serumurinsyre ved at konkurrere om proximal tubulus' udskillelse. Hos patienter med tendens til gigt: foretr\u00e6k losartanbaserede kombinationer (<a href=\"https:\/\/medsbase.com\/da\/cosart-h\/\">Cosart H<\/a>, <a href=\"https:\/\/medsbase.com\/da\/cozartan-h\/\">Cozartan H<\/a>) whose losartan component is uniquely uricosuric and offsets the thiazide urate rise. If Dytor is already in use and gout flares, add or continue urate-lowering therapy (allopurinol) rather than stopping Dytor outright.<\/p>\n<h3 class=\"wp-block-heading\">I&rsquo;m diabetic &mdash; is Dytor safe?<\/h3>\n<p>For det meste ja, men v\u00e6r opm\u00e6rksom p\u00e5 at thiazider og (i mindre grad) loop-diuretika <strong>forv\u00e6rrer glukosetolerancen beskedent<\/strong> (gennemsnitlig stigning i fastingglukose p\u00e5 5-8 mg\/dL, HbA1c 0,1-0,3%). Fordelen ved blodtrykss\u00e6nkningen opvejer dette for de fleste diabetikere. Hvis du \u00f8nsker en mere metabolsk neutral kombination, er ARB+CCB et alternativ (<a href=\"https:\/\/medsbase.com\/da\/olmezest-am\/\">Olmezest AM<\/a>).<\/p>\n<h3 class=\"wp-block-heading\">Can I take ibuprofen with Dytor?<\/h3>\n<p>Lejlighedsvis kortvarig brug er normalt fint. Kronisk daglig brug af NSAID'er (ibuprofen, diclofenac, naproxen) <strong>reducerer diuretisk og antihypertensiv effekt<\/strong> of Dytor (prostaglandin blockade) and substantially raise the AKI risk when combined with an ACE inhibitor or ARB &mdash; the &#8220;triple whammy.&#8221; Use paracetamol preferentially for chronic pain.<\/p>\n<h3 class=\"wp-block-heading\">Vil jeg skulle urinere mere om natten?<\/h3>\n<p>Usually no, if you take Dytor in the morning. The diuretic effect peaks 2-4 hours after dosing and has mostly worn off by evening. Nocturia is a common complaint when patients switch to evening dosing; switch back to morning dosing and nocturia resolves within 1-3 days.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Dytor in pregnancy?<\/h3>\n<p>Routinem\u00e6ssigt undg\u00e5et. Sl\u00f8jfedemidler passerer placentaen og kan p\u00e5virke fosteret. Ved hypertention under graviditet, skift til <a href=\"https:\/\/medsbase.com\/da\/labebet\/\">labetalol<\/a>, methyldopa eller nifedipin. Diuretika bruges kun under graviditet ved specifikke indikationer (lunge\u00f8dem, resistent HF) under specialistvejledning.<\/p>\n<h3 class=\"wp-block-heading\">Hvad hvis jeg glemmer en dosis?<\/h3>\n<p>Tag det s\u00e5 snart du husker det, medmindre det er n\u00e6sten tid til din n\u00e6ste dosis \u2014 i s\u00e5 fald spring den glemte dosis over. Tag ikke en dobbeltdosis. En enkelt glemt dosis p\u00e5virker ikke langtidsblodtrykket eller v\u00e6skebalancen markant.<\/p>\n<h3 class=\"wp-block-heading\">Where can I buy Dytor online?<\/h3>\n<p>You can buy Dytor (5 \/ 10 \/ 20 mg torasemide, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.<\/p>\n<h2 class=\"wp-block-heading\">Relaterede antihypertensiva og diuretika p\u00e5 MedsBase<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/amifru\/\">Amifru \u2014 Furosemid + Amilorid (loop + K-besparende)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/cosart-h\/\">Cosart H \u2014 Losartan + HCTZ fast kombination<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/losar\/\">Losar \u2014 Losartan (ARB-partner til diuretikum)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/natrilix-sr\/\">Natrilix SR \u2014 Indapamid 1,5 mg SR (thiazid-lignende)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/ramcor\/\">Ramcor \u2014 Ramipril (ACEi-partner til diuretikum)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/telmaheal\/\">Telmaheal \u2014 Telmisartan (ARB-partner til diuretikum)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/high-blood-pressure-medication\/\"><strong>Se alle h\u00f8jtryksmedicin<\/strong><\/a><\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:16px 20px;margin:24px 0;border-radius:4px;\"><strong>\u2695 Medicinsk ansvarsfraskrivelse.<\/strong> Denne side er kun til informationsform\u00e5l og erstatter ikke l\u00e6gefaglig r\u00e5dgivning fra en kvalificeret sundhedsfaglig person. Hypertension, hjerteinsufficiens og arytmier kr\u00e6ver diagnose, overv\u00e5gning og individuel dosering af en l\u00e6ge \u2014 brug altid beta-blokkere under l\u00e6gelig vejledning.<\/div>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterede alternativer<\/h3>\n<p>Andre produkter inden for <strong>Kroniske tilstande<\/strong> som kunder ogs\u00e5 ser:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/da\/voritrol\/\">Voritrol<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/glynase-mf\/\">Glynase-MF<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/arkamin-h\/\">Arkamin-H<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/fluvoxin\/\">Fluvoxin<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/da\/hydrosar\/\">Hydrosar<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>Dytor is Cipla&#8217;s torasemide 5\/10\/20 mg tablets \u2014 long-acting loop diuretic with 80-100% predictable bioavailability (vs furosemide 10-90%). Preferred in patients with gut oedema, inconsistent furosemide response, or needing once-daily loop coverage. Mild aldosterone antagonism reduces hypokalaemia. Only loop diuretic with reasonable hypertension evidence. TRANSFORM-HF 2023 \u2014 equivalent mortality to furosemide in heart failure.<\/p>","protected":false},"featured_media":0,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3260,3356],"product_tag":[4941,4942],"class_list":{"0":"post-60882","1":"product","2":"type-product","3":"status-publish","5":"product_cat-category-overview","6":"product_cat-chronic-conditions","7":"product_cat-heart-blood-pressure","8":"product_cat-high-blood-pressure-medication","9":"product_tag-dytor","10":"product_tag-torasemide","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product\/60882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/comments?post=60882"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/media?parent=60882"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_brand?post=60882"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_cat?post=60882"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/da\/wp-json\/wp\/v2\/product_tag?post=60882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}